RDGL - New Hope In Cancer Battle: FDA Grants Breakthrough Device Status To Vivos Inc.'s RadioGel | Benzinga
In a significant advancement for cancer therapy, the Food and Drug Administration (FDA) has awarded RadioGel Precision Radionuclide Therapy the coveted Breakthrough Device Designation. Developed by Vivos Inc. (OTCQB: RDGL), this designation marks a crucial milestone in the treatment of solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer.
How RadioGel Works
RadioGel, a pioneering Yttrium-90-based injectable brachytherapy device, represents a groundbreaking approach to cancer treatment. It is designed for patients who are either not eligible for surgery or have chosen not to undergo the procedure, particularly those with non-radioiodine avid disease and limited burden regional nodal disease.
The therapy involves directly injecting a hydrogel containing yttrium-90 phosphate microparticles into the tumor. This method allows for a more localized and potent radiation treatment compared ...